STAAR Surgical (NASDAQ:STAA) Posts Earnings Results, Misses Estimates By $0.03 EPS

STAAR Surgical (NASDAQ:STAA) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03), FiscalAI reports. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. The company had revenue of $93.52 million during the quarter, compared to the consensus estimate of $78.72 million. During the same period in the previous year, the business posted ($1.10) earnings per share. The firm’s revenue was up 119.6% on a year-over-year basis.

Here are the key takeaways from STAAR Surgical’s conference call:

• STAAR reported a strong Q1 2026 with net sales of $93.5 million, up 119.6% year over year, and adjusted EBITDA swung to a $24.4 million profit from a $26.3 million loss last year.
• China drove the quarter, with $47.4 million in sales, early demand for EVO+ ICL, and distributor inventory back within targeted levels, which management said makes the quarter a cleaner base going forward.
• The company said it is seeing operating leverage and margin improvement, with gross margin rising to 73.6% and operating expenses down 18% excluding special items, while still targeting $225 million in full-year 2026 spending.
• STAAR highlighted several growth catalysts, including FDA approval expanding EVO ICL to patients ages 45 to 60, continued U.S. momentum with sales above $6 million, and the global milestone of more than 4 million ICLs sold.
• Management remained cautious on guidance, declining to endorse consensus or give specific Q2/Q3 forecasts because of macro, geopolitical, and seasonal uncertainty, even though it said Q2 appears to be shaping up normally.

STAAR Surgical Trading Up 4.3%

STAA stock traded up $1.22 during trading on Wednesday, hitting $29.40. The company had a trading volume of 1,318,414 shares, compared to its average volume of 781,679. The company has a fifty day moving average price of $22.22 and a two-hundred day moving average price of $22.54. The company has a market cap of $1.46 billion, a P/E ratio of -18.04 and a beta of 1.20. STAAR Surgical has a fifty-two week low of $15.59 and a fifty-two week high of $30.81.

Insider Buying and Selling

In related news, Director Broadwood Partners, L.P. purchased 316,017 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the purchase, the director directly owned 16,123,842 shares in the company, valued at $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last quarter, insiders acquired 670,213 shares of company stock valued at $12,266,249. 39.90% of the stock is owned by insiders.

Hedge Funds Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning boosted its stake in STAAR Surgical by 39.1% in the third quarter. Creative Planning now owns 21,834 shares of the medical instruments supplier’s stock worth $587,000 after purchasing an additional 6,139 shares in the last quarter. Nomura Holdings Inc. acquired a new position in STAAR Surgical in the second quarter worth $502,000. State of Wisconsin Investment Board acquired a new position in STAAR Surgical in the fourth quarter worth $461,000. Hudson Bay Capital Management LP acquired a new position in STAAR Surgical in the fourth quarter worth $456,000. Finally, Brooklyn Investment Group boosted its stake in STAAR Surgical by 878.7% in the third quarter. Brooklyn Investment Group now owns 14,866 shares of the medical instruments supplier’s stock worth $399,000 after purchasing an additional 13,347 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of recent analyst reports. Wedbush raised their price objective on STAAR Surgical from $21.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, April 9th. Wall Street Zen raised STAAR Surgical to a “hold” rating in a research note on Saturday, April 11th. Canaccord Genuity Group raised STAAR Surgical from a “hold” rating to a “buy” rating and raised their price objective for the company from $22.00 to $27.00 in a research note on Thursday, April 9th. Morgan Stanley assumed coverage on STAAR Surgical in a research note on Friday, January 16th. They issued an “underweight” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings downgraded STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $19.93.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.